Tachyon Therapeutics
Tachyon Therapeutics is dedicated to accelerating the development of first-in-class therapeutics targeting significant new drug targets to fight cancer. They focus on novel pathways and mechanisms of tumorigenesis, with an initial focus on KDM4, an epigenetic regulator involved in cancer progression. Their mission is to create innovative therapies that address fundamental tumorigenic mechanisms and overcome drug resistance in cancer treatment.
Industries
Nr. of Employees
small (1-50)
Tachyon Therapeutics
San Francisco, California, United States, North America
Products
Oral pan-histone demethylase (KDM4) small-molecule clinical candidate
First-in-class, orally available pan-inhibitor of the KDM4 family of histone demethylases developed as a therapeutic candidate for treatment of advanced or metastatic solid tumors; advanced through preclinical studies and entered first-in-human Phase 1 clinical evaluation.
Oral pan-histone demethylase (KDM4) small-molecule clinical candidate
First-in-class, orally available pan-inhibitor of the KDM4 family of histone demethylases developed as a therapeutic candidate for treatment of advanced or metastatic solid tumors; advanced through preclinical studies and entered first-in-human Phase 1 clinical evaluation.
Expertise Areas
- Epigenetic target discovery and validation
- Small-molecule oncology drug discovery
- Preclinical pharmacology and efficacy testing
- Single-cell genomics and translational biomarker development
Key Technologies
- Single-cell genomic analysis
- Histone demethylase (KDM4) inhibition / epigenetic modulation
- Oral small-molecule inhibitor chemistry
- Patient-derived organoid culture